Journal of Clinical Pathways’ Post

Check out the latest issue of the Journal of Clinical Pathways! https://lnkd.in/egTcUy4H Featured stories include: Andrew Pecora, MD, et al provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US. Sabree C. Burbage, PharmD, et al details their study regarding prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs) with or without in-office dispensing (IOD) services using electronic medical record (EMR) data from community-based urology practices in the US. Randy Vogenberg, PhD, FASHP, et al discusses how there is a stakeholder disconnect in precision medicine, leaving employers and other commercial plans or administrators seeking solutions as they face emerging risks from precision therapies. Lee Blansett, MBA, summarizes the third part of a study by HMP Market Access Insights , which examined the influence and impact pathways have on oncologists’ treatment decisions. #JournalOfClinicalPathways #ValueBasedCare #CancerCare #TransformativeEmployerTrends #DecisionMaking #HealthCareRisks #PrecisionMedicine #HMPMarketAccessInsights #MAI #nmCRPC

Check out the latest issue of the Journal of Clinical Pathways! https://lnkd.in/egTcUy4H Featured stories include: Andrew Pecora, MD, et al provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US. Sabree C. Burbage, PharmD, et al details their study regarding prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs) with or without in-office dispensing (IOD) services using electronic medical record (EMR) data from community-based urology practices in the US. Randy Vogenberg, PhD, FASHP, et al discusses how there is a stakeholder disconnect in precision medicine, leaving employers and other commercial plans or administrators seeking solutions as they face emerging risks from precision therapies. Lee Blansett, MBA, summarizes the third part of a study by HMP Market Access Insights , which examined the influence and impact pathways have on oncologists’ treatment decisions. #JournalOfClinicalPathways #ValueBasedCare #CancerCare #TransformativeEmployerTrends #DecisionMaking #HealthCareRisks #PrecisionMedicine #HMPMarketAccessInsights #MAI #nmCRPC

Check out the latest issue of the Journal of Clinical Pathways! https://lnkd.in/egTcUy4H Featured stories include: Andrew Pecora, MD, et al provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US. Sabree C. Burbage, PharmD, et al details their study regarding prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs) with or without in-office dispensing (IOD) services using electronic medical record (EMR) data from community-based urology practices in the US. Randy Vogenberg, PhD, FASHP, et al discusses how there is a stakeholder disconnect in precision medicine, leaving employers and other commercial plans or administrators seeking solutions as they face emerging risks from precision therapies. Lee Blansett, MBA, summarizes the third part of a study by HMP Market Access Insights , which examined the influence and impact pathways have on oncologists’ treatment decisions. #JournalOfClinicalPathways #ValueBasedCare #CancerCare #TransformativeEmployerTrends #DecisionMaking #HealthCareRisks #PrecisionMedicine #HMPMarketAccessInsights #MAI #nmCRPC

Check out the latest issue of the Journal of Clinical Pathways! https://lnkd.in/egTcUy4H Featured stories include: Andrew Pecora, MD, et al provides insights and perspective from each constituent involved in shaping health care payment and delivery throughout the US. Sabree C. Burbage, PharmD, et al details their study regarding prostate-specific antigen (PSA) outcomes and clinical surveillance patterns among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) receiving next-generation androgen receptor inhibitors (ARIs) with or without in-office dispensing (IOD) services using electronic medical record (EMR) data from community-based urology practices in the US. Randy Vogenberg, PhD, FASHP, et al discusses how there is a stakeholder disconnect in precision medicine, leaving employers and other commercial plans or administrators seeking solutions as they face emerging risks from precision therapies. Lee Blansett, MBA, summarizes the third part of a study by HMP Market Access Insights , which examined the influence and impact pathways have on oncologists’ treatment decisions. #JournalOfClinicalPathways #ValueBasedCare #CancerCare #TransformativeEmployerTrends #DecisionMaking #HealthCareRisks #PrecisionMedicine #HMPMarketAccessInsights #MAI #nmCRPC

Over 25% of Americans skipped medical treatment last year due to costs - unacceptable.    At DecisionRx, we know that pharmacogenomics solutions get medication therapy right from the start through genetic analysis, avoiding costly side effects and trial/error prescribing.    This personalized approach has been shown to save more than $3,600 per patient per year while improving outcomes. Pharmacogenomics can increase medication efficacy while reducing overall costs - making quality care more affordable and accessible.    Read more: https://lnkd.in/e2aNK4wE    #PrecisionMedicine #ReducingHealthcareCosts #PersonalizedRx #pharmacogenomics